{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:18:54Z","timestamp":1765610334313},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the study by Johnston et al., gepants were meant to be taken to treat emergent migraine. It is tempting to speculate what the effect would be if patients were instructed to take a gepant as needed (PRN) or even prior to headache onset. While the latter sounds irrational at first glance, several studies have shown that a significant proportion of patients are quite proficient in predicting (or simply due to premonitory symptoms noting) their migraine attacks prior to the onset of actual headache. The study by Johnston et al. provides food for thought along these lines and should encourage us to further investigate flexible patient-controlled CGRP blocking as a third, intermediate and potentially cost-effective avenue between acute\/rescue treatment and prevention\/prophylaxis.<\/jats:p>","DOI":"10.1186\/s10194-023-01565-6","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T11:04:21Z","timestamp":1680174261000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Is the right way to go in between?"],"prefix":"10.1186","volume":"24","author":[{"given":"Andreas R.","family":"Gantenbein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kleinschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"issue":"1","key":"1565_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2514183x18823377","volume":"3","author":"H-C Diener","year":"2019","unstructured":"Diener H-C et al (2019) Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clin Transl Neurosci 3(1):3. https:\/\/doi.org\/10.1177\/2514183x18823377","journal-title":"Clin Transl Neurosci"},{"issue":"19","key":"1565_CR2","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M (2020) Migraine. N Engl J Med 383(19):1866\u20131876","journal-title":"N Engl J Med"},{"issue":"13","key":"1565_CR3","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.1990.03450130083031","volume":"264","author":"JE Buring","year":"1990","unstructured":"Buring JE, Peto R, Hennekens CH (1990) Low-dose aspirin for migraine prophylaxis. JAMA 264(13):1711\u20131713","journal-title":"JAMA"},{"issue":"10","key":"1565_CR4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1177\/0333102412473667","volume":"33","author":"J Schoenen","year":"2013","unstructured":"Schoenen J, Jensen RH, Lanteri-Minet M, Lainez MJ, Gaul C, Goodman AM, Caparso A, May A (2013) Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study. Cephalalgia 33(10):816\u2013830","journal-title":"Cephalalgia"},{"issue":"8","key":"1565_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1212\/WNL.0b013e3182825055","volume":"80","author":"J Schoenen","year":"2103","unstructured":"Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, G\u00e9rard P, Magis D (2103) Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 80(8):697\u2013704","journal-title":"Neurology"},{"issue":"1","key":"1565_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s10194-020-01204-4","volume":"21","author":"X Moisset","year":"2020","unstructured":"Moisset X, Pereira B, Ciampi de Andrade D, Fontaine D, Lant\u00e9ri-Minet M, Mawet J (2020) Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain 21(1):142. https:\/\/doi.org\/10.1186\/s10194-020-01204-4","journal-title":"J Headache Pain"},{"issue":"10","key":"1565_CR7","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/head.14007","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S (2020) Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. Headache 60(10):2220\u20132231","journal-title":"Headache"},{"issue":"11","key":"1565_CR8","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","volume":"83","author":"TW Ho","year":"2014","unstructured":"Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, Lines C, Edvinsson L, Goadsby PJ, Michelson D (2014) Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 83(11):958\u2013966","journal-title":"Neurology"},{"issue":"9","key":"1565_CR9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","volume":"19","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A (2020) Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol 19(9):727\u2013737","journal-title":"Lancet Neurol"},{"issue":"10268","key":"1565_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ (2021) Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet 397(10268):51\u201360","journal-title":"Lancet"},{"issue":"6","key":"1565_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/14737175.2022.2091435","volume":"22","author":"AA Argyriou","year":"2022","unstructured":"Argyriou AA, Mantovani E, Mitsikostas DD, Vikelis M, Tamburin S (2022) A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine. Expert Rev Neurother 22(6):469\u2013488","journal-title":"Expert Rev Neurother"},{"issue":"11","key":"1565_CR12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-019-00665-9","volume":"33","author":"C Chan","year":"2019","unstructured":"Chan C, Goadsby PJ (2019) Recent Advances in Pharmacotherapy for Episodic Migraine. CNS Drugs 33(11):1053\u20131071","journal-title":"CNS Drugs"},{"issue":"7","key":"1565_CR13","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/psp4.12196","volume":"6","author":"FT Musuamba","year":"2017","unstructured":"Musuamba FT et al (2017) Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA\/EFPIA Workshop on Dose Finding (London 4\u20135 December 2014). CPT Pharmacometrics Syst Pharmacol 6(7):418\u2013429","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"1565_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-021-01276-w","volume":"22","author":"AH Poulsen","year":"2021","unstructured":"Poulsen AH, Younis S, Thuraiaiyah J, Ashina M (2021) The chronobiology of migraine: a systematic review. J Headache Pain 22(1):76. https:\/\/doi.org\/10.1186\/s10194-021-01276-w","journal-title":"J Headache Pain"},{"issue":"1","key":"1565_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-021-01378-5","volume":"23","author":"K Johnston","year":"2022","unstructured":"Johnston K, Harris L, Powell L, Popoff E, Coric V, L\u2019Italien G, Schreiber CP (2022) Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201). J Headache Pain 23(1):10. https:\/\/doi.org\/10.1186\/s10194-021-01378-5","journal-title":"J Headache Pain"},{"issue":"7","key":"1565_CR16","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/WNL.0000000000001256","volume":"84","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC (2015) Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 84(7):688\u201395 (d)","journal-title":"Neurology"},{"issue":"6","key":"1565_CR17","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1212\/01.WNL.0000052998.58526.A9","volume":"60","author":"NJ Giffin","year":"2003","unstructured":"Giffin NJ, Ruggiero L, Lipton RB, Silberstein SD, Tvedskov JF, Olesen J, Altman J, Goadsby PJ, Macrae A (2003) Premonitory symptoms in migraine: an electronic diary study. Neurology 60(6):935\u2013940","journal-title":"Neurology"},{"issue":"10","key":"1565_CR18","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1111\/head.14025","volume":"60","author":"DC Buse","year":"2020","unstructured":"Buse DC, McGinley JS, Lipton RB (2020) Predicting the Future of Migraine Attack Prediction. Headache 60(10):2125\u20132128","journal-title":"Headache"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01565-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01565-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01565-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T11:04:25Z","timestamp":1680174265000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01565-6"}},"subtitle":["Rimegepant as needed provides preventive benefit. A comment on: monthly migraine days, tablet utilization, and quality of life associated with rimegepant\u2014post hoc results from an open label safety study (BHV3000\u2013201)"],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1565"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01565-6","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"assertion":[{"value":"8 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ARG has received honoraria for speaking or consulting from Amgen, Abbvie, Allergan, Biomed, Curatis, EliLilly, Lundbeck, Novartis, Sanofi and TEVA.AK has received honoraria for consulting from Abbvie, EliLilly, Lundbeck, Mitsubishi Tanabe, Novartis, and TEVA that were paid to a teaching and research fund at the University Hospital Geneva.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}